Drug | Description | Mechanism | Route of Administration | Potential clinical application | Phase of development | Participants | Status | References |
---|---|---|---|---|---|---|---|---|
EA-230 | Oligopeptide fragment from b-hCG | Immunomodulation | Intravenous | Sepsis | Phase 2 | 60 | Completed | NCT02629874 |
hLF1-11 | A synthetic cationic peptide; A peptide comprising the first eleven residues of hLF | Immunomodulation, direct antibacterial activity | Intravenous | Treatment of infectious complications among haematopoietic stem cell transplant (HSCT) recipients | Phase 2 | 8 | Completed | NCT00509938 |
IMX-942 | A synthetic cationic peptide; A derivative of IDR-1 | Immunomodulation | Intravenous | Treatment of oral complication in patients being treated with chemotherapy | Phase 3 | 268 | Completed | NCT03237325 |
AB103 | A synthetic peptide mimetic of the T-lymphocyte receptor, CD28 | Immunomodulation | Intravenous | Necrotizing soft tissue infections | Phase 3 | 290 | Completed | NCT02469857 |
Talactoferrin | A recombinant form of the human glycoprotein, lactoferrin | Immunomodulation | Oral | Sepsis | Phase 2/3 | 1280 | Suspended | NCT01273779 |
Omiganan | A synthetic cationic peptide; derivative of indolicidin | Immunomodulation | Topical | Topical antiseptic | Phase 3 | 30 | Completed | NCT00608959 |
Brilacidin | A small molecule arylamide mimic of defensin | Direct antibacterial, potential immunomodulatory activities | Intravenous | Treatment of acute S. aureus skin and skin structure infections | Phase 2b | 215 | Completed | NCT02052388 |
rBPI21 | Synthetic peptide | Direct antibacterial, potential immunomodulatory activities | Intravenous | Reduction of LPS-induced inflammatory sequelae, in particular aGvHD, in patients undergoing allogeneic HSCT | Phase 2 | 6 | Terminated due to the lack of enrollment | NCT00454155 |